ImmunoGen Wants A Bigger Share Of The Antibody-Drug Conjugate Pie
This article was originally published in The Pink Sheet Daily
The company touted its proprietary pipeline at an investor day as it turns its focus away from partnerships and toward its internal research.
You may also be interested in...
The anticipated success of the recently filed T-DM1 has offered ImmunoGen the opportunity to shine a light on its own ADC efforts.
Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.
Private equity firm Celtic Therapeutics is promising a $50 million investment in ADC Therapeutics, a new company that will work closely with Celtic’s other investment Spirogen on antibody-drug conjugates.